Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cerilliant
McKinsey
Deloitte
Mallinckrodt
QuintilesIMS
Chinese Patent Office
Cipla
AstraZeneca
Colorcon

Generated: October 16, 2017

DrugPatentWatch Database Preview

ZUPLENZ Drug Profile

« Back to Dashboard

Which patents cover Zuplenz, and what generic Zuplenz alternatives are available?

Zuplenz is a drug marketed by Midatech Pharma Us and is included in one NDA. There are two patents protecting this drug.

This drug has fourteen patent family members in ten countries.

The generic ingredient in ZUPLENZ is ondansetron. There are twenty-eight drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the ondansetron profile page.

Summary for Tradename: ZUPLENZ

US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list77
Clinical Trials: see list1
Patent Applications: see list5,319
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZUPLENZ at DailyMed

Pharmacology for Tradename: ZUPLENZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Midatech Pharma Us
ZUPLENZ
ondansetron
FILM;ORAL022524-001Jul 2, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Midatech Pharma Us
ZUPLENZ
ondansetron
FILM;ORAL022524-002Jul 2, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Midatech Pharma Us
ZUPLENZ
ondansetron
FILM;ORAL022524-001Jul 2, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Midatech Pharma Us
ZUPLENZ
ondansetron
FILM;ORAL022524-002Jul 2, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZUPLENZ

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,682,037Non-mucoadhesive film dosage forms► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZUPLENZ

Country Document Number Estimated Expiration
Canada2664986► Subscribe
Australia2007304425► Subscribe
World Intellectual Property Organization (WIPO)2008040534► Subscribe
South Korea101448050► Subscribe
South Korea20090080037► Subscribe
Germany202007019476► Subscribe
European Patent Office2076251► Subscribe
BrazilPI0719840► Subscribe
European Patent Office2444072► Subscribe
Mexico2009003372► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Farmers Insurance
Colorcon
Mallinckrodt
Citi
Express Scripts
Merck
Accenture
QuintilesIMS
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot